Fries JF, Holman HR. Systemic lupus erythematosus: a clinical analysis. In: Smith LH, editor. Major Problems in Internal Medicine. Philadelphia, London, Toronto: W.B. Sauners; 1975. p. 8–20.
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86.
Enocsson H, Sjöwall C, Wirestam L, Dahle C, Kastbom A, Rönnelid J, Wetterö J, Skogh T. Four anti-dsDNA antibody assays in relation to systemic lupus erythematosus disease specificity and activity. J Rheumatol. 2015;42:817–25.
Trouw LA, Daha MR. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther. 2005;5:243–51.
Frodlund M, Dahlström Ö, Kastbom A, Skogh T, Sjöwall C. Associations between antinuclear antibody staining patterns and clinical features of systemic lupus erythematosus: analysis of a regional Swedish register. BMJ Open. 2013;3, e003608.
Burgos PI, Alarcón GS. Thrombosis in systemic lupus erythematosus: risk and protection. Expert Rev Cardiovasc Ther. 2009;7:1541–9.
van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol. 2011;7:391–8.
Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58:1576–81.
Kakumanu P, Sobel ES, Narain S, et al. Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol. 2009;36:2682–90.
Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA. 2011;108:17372–7.
Jiang X, Trouw LA, van Wesemael TJ, et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann Rheum Dis. 2014;73:1761–8.
Koppejan H, Trouw LA, Sokolove J, Sokolove J, Lahey LJ, Huizinga TJ, Smolik IA, Robinson DB, El-Gabalawy HS, Toes RE, Hitchon CA. Role of Anti-carbamylated protein antibodies compared to anti-citrullinated protein antibodies in indigenous north Americans with rheumatoid arthritis, their first-degree relatives, and healthy controls. Arthritis Rheumatol. 2016;68:2090–8.
Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, Toes RE, Trouw LA. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780–3.
Brink M, Verheul MK, Rönnelid J, Berglin E, Holmdahl R, Toes RE, Klareskog L, Trouw LA, Rantapää-Dahlqvist S. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res Ther. 2015;17:25.
Gan RW, Trouw LA, Shi J, et al. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J Rheumatol. 2015;42:572–9.
Shi J, van Veelen PA, Mahler M, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev. 2014;13:225–30.
Montes A, Regueiro C, Perez-Pampin E, Boveda MD, Gomez-Reino JJ, Gonzalez A. Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS One. 2016;11, e0161141.
Ajeganova S, van Steenbergen HW, Verheul MK, et al. The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Ann Rheum Dis. 2016. doi:10.1136/annrheumdis-2015-208870.
Bergum B, Koro C, Delaleu N, et al. Antibodies against carbamylated proteins are present in primary Sjögren’s syndrome and are associated with disease severity. Ann Rheum Dis. 2016;75:1494–500.
Scinocca M, Bell DA, Racapé M, et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol. 2014;41:270–9.
López-Hoyos M, Álvarez-Rodríguez L, Mahler M, Torices S, Calvo-Alén J, Villa I, Seaman A, Yee A, Martínez-Taboada V. Anti-carbamylated protein antibodies in patients with ageing associated inflammatory chronic disorders. Rheumatology (Oxford). 2016;55:764–6.
Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol. 2009;23:495–506.
Petri M. Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. Arthritis Care Res (Hoboken). 1995;8:137–45.
Richter Cohen M, Steiner G, Smolen JS, Isenberg DA. Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol. 1998;37:421–4.
Panush RS, Edwards NL, Longley S, Webster E. ‘Rhupus’ syndrome. Arch Intern Med. 1988;148:1633–6.
Fernandez A, Quintana G, Rondon F, et al. Lupus arthropathy: a case series of patients with rhupus. Clin Rheumatol. 2006;25:164–7.
Amezcua-Guerra LM. Overlap between systemic lupus erythematosus and rheumatoid arthritis: is it real or just an illusion? J Rheumatol. 2009;36:4–6.
McGonagle D, Tan AL. What magnetic resonance imaging has told us about the pathogenesis of rheumatoid arthritis – the first 50 years. Arthritis Res Ther. 2008;10:222.
Ostendorf B, Scherer A, Specker C, Modder U, Schneider M. Jaccoud’s arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum. 2003;48:157–65.
Sa Ribeiro D, Galvao V, Luiz Fernandes J, et al. Magnetic resonance imaging of Jaccoud’s arthropathy in systemic lupus erythematosus. Joint Bone Spine. 2010;77:241–5.
Tani C, D’Aniello D, Delle Sedie A, et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmun Rev. 2013;12:537–41.
Ball EM, Tan AL, Fukuba E, McGonagle D, Grey A, Steiner G, Bell AL, Rooney MR. A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status. Rheumatology (Oxford). 2014;53:1835–43.
Zayat AS, Md Yusof MY, Wakefield RJ, Conaghan PG, Emery P, Vital EM. The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature review. Rheumatology (Oxford). 2016;55:485–94.
Ighe A, Dahlström O, Skogh T, Sjöwall C. Application of the 2012 Systemic Lupus International Collaborating Clinics classification criteria to patients in a regional Swedish systemic lupus erythematosus register. Arthritis Res Ther. 2015;17:3.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
Ekdahl C, Eberhardt K, Andersson SI, Svensson B. Assessing disability in patients with rheumatoid arthritis. Use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol. 1988;17:263–71.
Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39:2118–26.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, Alfredsson L, EIRA study group. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis. 2003;62:835–41.
Kerkman PF, Fabre E, van der Voort EI, et al. Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1170–76.
Szkudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, Østergaard M. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging. Arthritis Rheum. 2001;44:2018–23.
Szkudlarek M, Court-Payen M, Jacobsen S, Klarlund M, Thomsen HS, Østergaard M. Interobserver agreement in ultrasonography of the finger and toe joints in rheumatoid arthritis. Arthritis Rheum. 2003;48:955–62.
Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.
Boeters DM, Nieuwenhuis WP, Verheul MK, Newsum EC, Reijnierse M, Toes RE, Trouw LA, van der Helm-van Mil AH. MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. Arthritis Res Ther. 2016;18:179.
Mediwake R, Isenberg DA, Schellekens GA, van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis. 2001;60:67–8.
Amezcua-Guerra LM, Márquez-Velasco R, Bojalil R. Erosive arthritis in systemic lupus erythematosus is associated with high serum C-reactive protein and anti-cyclic citrullinated peptide antibodies. Inflamm Res. 2008;57:555–7.
Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, McHugh NJ. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol. 2008;35:77–83.
Skare TL, Nisihara R, Barbosa BB, da Luz A, Utiyama S, Picceli V. Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients. Clin Rheumatol. 2013;32:1065–70.
Budhram A, Chu R, Rusta-Sallehy S, Ioannidis G, Denburg JA, Adachi JD, Haaland DA. Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus. 2014;23:1156–63.
Amaya-Amaya J, Molano-González N, Franco JS, Rodríguez-Jiménez M, Rojas-Villarraga A, Anaya JM. Anti-CCP antibodies as a marker of rhupus. Lupus. 2015;24:892–4.
Gustafsson JT, Gunnarsson I, Källberg H, et al. Cigarette smoking, antiphospholipid antibodies and vascular events in systemic lupus erythematosus. Ann Rheum Dis. 2015;74:1537–43.
Svärd A, Skogh T, Alfredsson L, Ilar A, Klareskog L, Bengtsson C, Kastbom A. Associations with smoking and shared epitope differ between IgA- and IgG-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis. Arthritis Rheumatol. 2015;67:2032–7.
Wright S, Filippucci E, Grassi W, Grey A, Bell A. Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus. 2006;15:501–6.
Zoma A. Musculoskeletal involvement in systemic lupus erythematosus. Lupus. 2004;13:851–3.
Delle Sedie A, Riente L, Scirè CA, et al. Ultrasound imaging for the rheumatologist. XXIV. Sonographic evaluation of wrist and hand joint and tendon involvement in systemic lupus erythematosus. Clin Exp Rheumatol. 2009;27:897–901.
Peterson CM, Tsairis P, Onishi A, Lu YS, Grady R. Sodium cyanate induced polyneuropathy in patients with sickle-cell disease. Ann Intern Med. 1974;81:152–8.
Crist RD, Grisolia S, Bettis CJ, Grisolia J. Carbamoylation of proteins following administration to rats of carbamoyl phosphate and cyanate and effects on memory. Eur J Biochem. 1973;32:109–16.
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.
Mohammad AJ, Weiner M, Sjöwall C, Johansson ME, Bengtsson AA, Ståhl-Hallengren C, Nived O, Eriksson P, Sturfelt G, Segelmark M. Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. Nephrol Dial Transplant. 2015;30 Suppl 1:i23–30.
Verheul MK, van Erp SJ, van der Woude D, et al. Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. Ann Rheum Dis. 2016;75:1575–6.